ATE433973T1 - Azolylaminoazine als inhibitoren von proteinkinasen - Google Patents

Azolylaminoazine als inhibitoren von proteinkinasen

Info

Publication number
ATE433973T1
ATE433973T1 AT03744682T AT03744682T ATE433973T1 AT E433973 T1 ATE433973 T1 AT E433973T1 AT 03744682 T AT03744682 T AT 03744682T AT 03744682 T AT03744682 T AT 03744682T AT E433973 T1 ATE433973 T1 AT E433973T1
Authority
AT
Austria
Prior art keywords
inhibitors
protein kinases
azolylaminoazines
compositions
compounds
Prior art date
Application number
AT03744682T
Other languages
English (en)
Inventor
David Bebbington
Hayley Binch
Jean-Damien Charrier
Simon Everitt
Julian Golec
David Kay
Ronald Knegtel
Andrew Miller
Francoise Pierard
Original Assignee
Vertex Pharma
David Bebbington
Hayley Binch
Jean-Damien Charrier
Simon Everitt
Golec Julian M C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma, David Bebbington, Hayley Binch, Jean-Damien Charrier, Simon Everitt, Golec Julian M C filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE433973T1 publication Critical patent/ATE433973T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03744682T 2002-03-15 2003-03-14 Azolylaminoazine als inhibitoren von proteinkinasen ATE433973T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36484002P 2002-03-15 2002-03-15
PCT/US2003/007904 WO2003078426A1 (en) 2002-03-15 2003-03-14 Azolylaminoazine as inhibitors of protein kinases

Publications (1)

Publication Number Publication Date
ATE433973T1 true ATE433973T1 (de) 2009-07-15

Family

ID=28041971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744682T ATE433973T1 (de) 2002-03-15 2003-03-14 Azolylaminoazine als inhibitoren von proteinkinasen

Country Status (6)

Country Link
US (1) US7179826B2 (de)
EP (1) EP1485381B8 (de)
AT (1) ATE433973T1 (de)
AU (1) AU2003225800A1 (de)
DE (1) DE60327999D1 (de)
WO (1) WO2003078426A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) * 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
KR20040084896A (ko) * 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
WO2003088959A2 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
MXPA05001367A (es) 2002-08-02 2005-04-28 Vertex Pharma Composiciones de pirazol utiles como inhibidores de gsk-3.
DK2316831T3 (da) * 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
EP1608631A4 (de) 2003-03-28 2008-08-20 Scios Inc Bicyclische pyrimidininhibitoren von tgf beta
EP1663994B1 (de) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydrochinazolin-verbindungen als inhibitoren von spannungsabhängigen ionenkanälen
CN1902193B (zh) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
KR20070058602A (ko) 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 저해 바이-사이클릭 피리미딘
EP1812439B2 (de) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
US7528132B2 (en) * 2005-01-26 2009-05-05 Schering Corporation Kinase inhibitors
BRPI0609650A2 (pt) 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
CA2603204A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
WO2007011721A1 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
US7737151B2 (en) * 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
BRPI0616630B8 (pt) * 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5249770B2 (ja) * 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
CA2668429A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
NZ577768A (en) * 2006-12-19 2012-01-12 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
CA2675558A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
JP5393489B2 (ja) * 2007-03-09 2014-01-22 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
CN101663295B (zh) * 2007-03-09 2014-11-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶类化合物
MX2009011059A (es) 2007-04-13 2009-11-26 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
WO2008137619A2 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AU2008247594A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CA2688584A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
US20100209488A1 (en) * 2007-07-16 2010-08-19 The Regents Of The University Of California Protein kinase modulating compounds and methods for making and using them
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
EA019104B1 (ru) * 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
MX2010013682A (es) * 2008-06-11 2011-03-15 Astrazeneca Ab Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
AU2009288200A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
EP2440052A4 (de) * 2009-06-08 2013-01-23 Abraxis Bioscience Llc Triazinderivate und deren therapeutische anwendungen
CA2764785C (en) * 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
EP2440053A4 (de) * 2009-06-09 2012-10-31 California Capital Equity Llc Benzylsubstituierte triazinderivate und ihre therapeutischen anwendungen
CN102573481A (zh) * 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 脲基苯基取代的三嗪衍生物及其治疗应用
WO2010144423A1 (en) * 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Styryl-triazine derivatives and their therapeutical applications
CA2765030C (en) * 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
AU2010333338A1 (en) 2009-12-14 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
EP2611789A1 (de) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Chinazolinverbindungen und anwendungsverfahren dafür
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
MX2014009933A (es) 2012-02-17 2015-12-16 Abbvie Inc Diaminopirimidinas utiles como inhibidores del virus sincitial respiratorio humano (rsv).
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US10163049B2 (en) 2013-03-08 2018-12-25 Microsoft Technology Licensing, Llc Inconspicuous tag for generating augmented reality experiences
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015029188A1 (ja) * 2013-08-29 2015-03-05 株式会社日立製作所 計算機及びデータ読み出し方法
EP3070084A1 (de) * 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. Neue fyn-kinase-inhibitoren
EP3630118A4 (de) 2017-05-23 2021-03-31 MEI Pharma, Inc. Kombinationstherapie
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) * 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase

Also Published As

Publication number Publication date
US7179826B2 (en) 2007-02-20
DE60327999D1 (de) 2009-07-30
EP1485381A1 (de) 2004-12-15
EP1485381B1 (de) 2009-06-17
AU2003225800A1 (en) 2003-09-29
EP1485381B8 (de) 2010-05-12
WO2003078426A1 (en) 2003-09-25
US20040002496A1 (en) 2004-01-01

Similar Documents

Publication Publication Date Title
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
NO20074446L (no) DR5-antistoffer og anvendelser derav
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties